Renal Transplantation


1.Guyatt, G.H., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 2008. 336: 924.

2.Guyatt, G.H., et al. What is “quality of evidence” and why is it important to clinicians? BMJ, 2008. 336: 995.

3.Phillips B, et al. Oxford Centre for Evidence-based Medicine Levels of Evidence. Updated by Jeremy Howick March 2009. 1998.

4.Guyatt, G.H., et al. Going from evidence to recommendations. BMJ, 2008. 336: 1049.

5.Boissier, R., et al. Benefits and harms of benign prostatic obstruction treatments in renal transplanted patients. PROSPERO, 2019. CRD42019136477.

6.Boissier, R., et al. Effectiveness of interventions on nephrolithiasis in transplanted kidney. PROSPERO, 2019. CRD42019136474.

7.Lennerling, A., et al. Living organ donation practices in Europe - results from an online survey. Transpl Int, 2013. 26: 145.

8.Antcliffe, D., et al. A meta-analysis of mini-open versus standard open and laparoscopic living donor nephrectomy. Transpl Int, 2009. 22: 463.

9.Greco, F., et al. Laparoscopic living-donor nephrectomy: analysis of the existing literature. Eur Urol, 2010. 58: 498.

10.Wilson, C.H., et al. Laparoscopic versus open nephrectomy for live kidney donors. Cochrane Database Syst Rev, 2011: CD006124.

11.Yuan, H., et al. The safety and efficacy of laparoscopic donor nephrectomy for renal transplantation: an updated meta-analysis. Transplant Proc, 2013. 45: 65.

12.Serrano, O.K., et al. Evolution of Living Donor Nephrectomy at a Single Center: Long-Term Outcomes with 4 Different Techniques in Greater Than 4000 Donors over 50 Years. Transplantation, 2016. 100: 1299.

13.Breda, A., et al. Mini-laparoscopic live donor nephrectomy with the use of 3-mm instruments and laparoscope. World J Urol, 2015. 33: 707.

14.Elmaraezy, A., et al. Should hand-assisted retroperitoneoscopic nephrectomy replace the standard laparoscopic technique for living donor nephrectomy? A meta-analysis. International Journal of Surgery, 2017. 40: 83.

15.Creta, M., et al. Donor and Recipient Outcomes following Robotic-Assisted Laparoscopic Living Donor Nephrectomy: A Systematic Review. Biomed Res Int, 2019. 2019: 1729138.

16.Lentine, K.L., et al. Perioperative Complications After Living Kidney Donation: A National Study. Am J Transplant, 2016. 16: 1848.

17.Wang, H., et al. Robot-assisted laparoscopic vs laparoscopic donor nephrectomy in renal transplantation: A meta-analysis. Clin Transplant, 2019. 33: e13451.

18.Autorino, R., et al. Laparoendoscopic single-site (LESS) vs laparoscopic living-donor nephrectomy: a systematic review and meta-analysis. BJU Int, 2015. 115: 206.

19.Gupta, A., et al. Laparoendoscopic single-site donor nephrectomy (LESS-DN) versus standard laparoscopic donor nephrectomy [Systematic Review]. Cochrane Database Syst Rev, 2016. 6: 6.

20.Alcaraz, A., et al. Feasibility of transvaginal natural orifice transluminal endoscopic surgery-assisted living donor nephrectomy: is kidney vaginal delivery the approach of the future? Eur Urol, 2011.
59: 1019.

21.Liu, N., et al. Maximizing the donor pool: left versus right laparoscopic live donor nephrectomy--systematic review and meta-analysis. Int Urol Nephrol, 2014. 46: 1511.

22.Khalil, A., et al. Trends and outcomes in right vs. left living donor nephrectomy: An analysis of the OPTN/UNOS database of donor and recipient outcomes - should we be doing more right-sided nephrectomies? Clinical Transplantation, 2016. 30: 145.

23.Hsi, R.S., et al. Analysis of techniques to secure the renal hilum during laparoscopic donor nephrectomy: review of the FDA database. Urology, 2009. 74: 142.

24.Hsi, R.S., et al. Mechanisms of hemostatic failure during laparoscopic nephrectomy: review of Food and Drug Administration database. Urology, 2007. 70: 888.

25.Ponsky, L., et al. The Hem-o-lok clip is safe for laparoscopic nephrectomy: a multi-institutional review. Urology, 2008. 71: 593.

26.Allen, M.B., et al. Donor hemodynamics as a predictor of outcomes after kidney transplantation from donors after cardiac death. Am J Transplant, 2016. 16: 181.

27.Heylen, L., et al. The duration of asystolic ischemia determines the risk of graft failure after circulatory-dead donor kidney transplantation: A Eurotransplant cohort study. Am J Transplant, 2018. 18: 881.

28.Osband, A.J., et al. Extraction Time of Kidneys from Deceased Donors and Impact on Outcomes. Am J of Transplant, 2016. 16: 700.

29.Redfield, R.R., et al. Predictors and outcomes of delayed graft function after living-donor kidney transplantation. Transpl Int, 2016. 29: 81.

30.Irish, W.D., et al. A risk prediction model for delayed graft function in the current era of deceased donor renal transplantation. Am J Transplant, 2010. 10: 2279. Boer, J., et al. Eurotransplant randomized multicenter kidney graft preservation study comparing HTK with UW and Euro-Collins. Transpl Int, 1999. 12: 447.

32.Parsons, R.F., et al. Preservation solutions for static cold storage of abdominal allografts: which is best? Curr Opin Organ Transplant, 2014. 19: 100.

33.Tillou, X., et al. Comparison of UW and Celsior: long-term results in kidney transplantation. Ann Transplant, 2013. 18: 146.

34.Barnett, D., Black, D. W., Buckley, B., Campbell, D., Clarke, P.,. Machine perfusion systems and cold static storage of kidneys from deceased donors. NICE Guidelines. Technology appraisal guidance 2009.

35.Kay, M.D., et al. Comparison of preservation solutions in an experimental model of organ cooling in kidney transplantation. Br J Surg, 2009. 96: 1215.

36.Bond, M., et al. The effectiveness and cost-effectiveness of methods of storing donated kidneys from deceased donors: a systematic review and economic model. Health Technol Assess, 2009. 13: iii.

37.Lledo-Garcia, E., et al. Spanish consensus document for acceptance and rejection of kidneys from expanded criteria donors. Clin Transplant, 2014. 28: 1155.

38.Johnston, T.D., et al. Sensitivity of expanded-criteria donor kidneys to cold ischaemia time. Clin Transplant, 2004. 18 Suppl 12: 28.

39.Peters-Sengers, H., et al. Impact of Cold Ischemia Time on Outcomes of Deceased Donor Kidney Transplantation: An Analysis of a National Registry. Transplant Direct, 2019. 5: e448.

40.Summers, D.M., et al. Analysis of factors that affect outcome after transplantation of kidneys donated after cardiac death in the UK: a cohort study. Lancet, 2010. 376: 1303.

41.Aubert, O., et al. Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study. BMJ, 2015. 351: h3557.

42.Kayler, L.K., et al. Impact of cold ischemia time on graft survival among ECD transplant recipients: a paired kidney analysis. Am J Transplant, 2011. 11: 2647.

43.Chatauret, N., et al. Preservation strategies to reduce ischemic injury in kidney transplantation: pharmacological and genetic approaches. Curr Opin Organ Transplant, 2011. 16: 180.

44.Jochmans, I., et al. Past, Present, and Future of Dynamic Kidney and Liver Preservation and Resuscitation. Am J Transplant, 2016. 16: 2545.

45.O’Callaghan, J.M., et al. Systematic review and meta-analysis of hypothermic machine perfusion versus static cold storage of kidney allografts on transplant outcomes. Br J Surg, 2013. 100: 991.

46.Martinez Arcos, L., et al. Functional Results of Renal Preservation in Hypothermic Pulsatile Machine Perfusion Versus Cold Preservation: Systematic Review and Meta-Analysis of Clinical Trials. Transplant Proc, 2018. 50: 24.

47.Tingle, S.J., et al. Machine perfusion preservation versus static cold storage for deceased donor kidney transplantation. Cochrane Database Syst Rev, 2019. 3: CD011671.

48.Jochmans, I., et al. Machine perfusion versus cold storage for the preservation of kidneys donated after cardiac death: a multicenter, randomized, controlled trial. Ann Surg, 2010. 252: 756.

49.Reznik, O.N., et al. Machine perfusion as a tool to select kidneys recovered from uncontrolled donors after cardiac death. Transplant Proc, 2008. 40: 1023.

50.Jochmans, I., et al. Hypothermic machine perfusion of kidneys retrieved from standard and high-risk donors. Transpl Int, 2015. 28: 665.

51.Treckmann, J., et al. Machine perfusion versus cold storage for preservation of kidneys from expanded criteria donors after brain death. Transpl Int, 2011. 24: 548.

52.Gill, J., et al. Pulsatile perfusion reduces the risk of delayed graft function in deceased donor kidney transplants, irrespective of donor type and cold ischemic time. Transplantation, 2014. 97: 668.

53.Matsuno, N., et al. Machine perfusion preservation for kidney grafts with a high creatinine from uncontrolled donation after cardiac death. Transplant Proc, 2010. 42: 155.

54.Jochmans, I., et al. Graft quality assessment in kidney transplantation: not an exact science yet! Curr Opin Organ Transplant, 2011. 16: 174.

55.Jochmans, I., et al. Oxygenated Hypothermic Machine Perfusion of Kidneys Donated after Circulatory Death: An International Randomised Controlled Trial [abstract]. Am J Transplant, 2019. 19.

56.Hosgood, S.A., et al. Normothermic machine perfusion of the kidney: better conditioning and repair? Transpl Int, 2015. 28: 657.

57.Reddy, S.P., et al. Normothermic perfusion: a mini-review. Transplantation, 2009. 87: 631.

58.Antoine, C., et al. Kidney Transplant From Uncontrolled Donation After Circulatory Death: Contribution of Normothermic Regional Perfusion. Transplantation, 2020. 104: 130.

59.Reznik, O., et al. Kidney from uncontrolled donors after cardiac death with one hour warm ischemic time: resuscitation by extracorporal normothermic abdominal perfusion “in situ” by leukocytes-free oxygenated blood. Clin Transplant, 2011. 25: 511.

60.Hosgood, S.A., et al. Ex vivo normothermic perfusion for quality assessment of marginal donor kidney transplants. Br J Surg, 2015. 102: 1433.

61.Hoyer, D.P., et al. Subnormothermic machine perfusion for preservation of porcine kidneys in a donation after circulatory death model. Transpl Int, 2014. 27: 1097.

62.Naesens, M. Zero-Time Renal Transplant Biopsies: A Comprehensive Review. Transplantation, 2016. 100: 1425.

63.Kasiske, B.L., et al. The role of procurement biopsies in acceptance decisions for kidneys retrieved for transplant. Clin J Am Soc Nephrol, 2014. 9: 562.

64.Marrero, W.J., et al. Predictors of Deceased Donor Kidney Discard in the United States. Transplantation, 2016.

65.Sung, R.S., et al. Determinants of discard of expanded criteria donor kidneys: impact of biopsy and machine perfusion. Am J Transplant, 2008. 8: 783.

66.Wang, C.J., et al. The Donor Kidney Biopsy and Its Implications in Predicting Graft Outcomes:
A Systematic Review. Am J Transplant, 2015. 15: 1903.

67.Hopfer, H., et al. Assessment of donor biopsies. Curr Opin Organ Transplant, 2013. 18: 306.

68.Gaber, L.W., et al. Glomerulosclerosis as a determinant of posttransplant function of older donor renal allografts. Transplantation, 1995. 60: 334.

69.Solez, K., et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant, 2008. 8: 753.

70.De Vusser, K., et al. The predictive value of kidney allograft baseline biopsies for long-term graft survival. J Am Soc Nephrol, 2013. 24: 1913.

71.Anglicheau, D., et al. A simple clinico-histopathological composite scoring system is highly predictive of graft outcomes in marginal donors. Am J Transplant, 2008. 8: 2325.

72.Balaz, P., et al. Identification of expanded-criteria donor kidney grafts at lower risk of delayed graft function. Transplantation, 2013. 96: 633.

73.Lopes, J.A., et al. Evaluation of pre-implantation kidney biopsies: comparison of Banff criteria to a morphometric approach. Kidney Int, 2005. 67: 1595.

74.Munivenkatappa, R.B., et al. The Maryland aggregate pathology index: a deceased donor kidney biopsy scoring system for predicting graft failure. Am J Transplant, 2008. 8: 2316.

75.Liapis, H., et al. Banff Histopathological Consensus Criteria for Preimplantation Kidney Biopsies. Am J Transplant, 2016.

76.Haas, M. Donor kidney biopsies: pathology matters, and so does the pathologist. Kidney Int, 2014. 85: 1016.

77.Azancot, M.A., et al. The reproducibility and predictive value on outcome of renal biopsies from expanded criteria donors. Kidney Int, 2014. 85: 1161.

78.Peters, B., et al. Sixteen Gauge biopsy needles are better and safer than 18 Gauge in native and transplant kidney biopsies. Acta Radiol, 2017. 58: 240.

79.Haas, M., et al. Arteriosclerosis in kidneys from healthy live donors: comparison of wedge and needle core perioperative biopsies. Arch Pathol Lab Med, 2008. 132: 37.

80.Mazzucco, G., et al. The reliability of pre-transplant donor renal biopsies (PTDB) in predicting the kidney state. A comparative single-centre study on 154 untransplanted kidneys. Nephrol Dial Transplant, 2010. 25: 3401.

81.Wang, H.J., et al. On the influence of sample size on the prognostic accuracy and reproducibility of renal transplant biopsy. Nephrol Dial Transplant, 1998. 13: 165.

82.Yushkov, Y., et al. Optimized technique in needle biopsy protocol shown to be of greater sensitivity and accuracy compared to wedge biopsy. Transplant Proc, 2010. 42: 2493.

83.Muruve, N.A., et al. Are wedge biopsies of cadaveric kidneys obtained at procurement reliable? Transplantation, 2000. 69: 2384.

84.Randhawa, P. Role of donor kidney biopsies in renal transplantation. Transplantation, 2001. 71: 1361.

85.Bago-Horvath, Z., et al. The cutting (w)edge--comparative evaluation of renal baseline biopsies obtained by two different methods. Nephrol Dial Transplant, 2012. 27: 3241.

86.Jankovic, Z. Anaesthesia for living-donor renal transplant. Current Anaesthesia & Critical Care, 2008. 19: 175.

87.Karmarkar, S., et al. Kidney Transplantation. Anaesthesia And Intensive Care Medicine 2009. 10.5.

88.Abramowicz, D., et al. European Renal Best Practice Guideline on kidney donor and recipient evaluation and perioperative care. Nephrol Dial Transplant, 2015. 30: 1790.

89.Van Loo, A.A., et al. Pretransplantation hemodialysis strategy influences early renal graft function.
J Am Soc Nephrol, 1998. 9: 473.

90.Task Force for Preoperative Cardiac Risk, A., et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J, 2009.
30: 2769.

91.Douketis, J.D., et al. Perioperative Management of Antithrombotic Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012. 141.

92.Benahmed, A., et al. Ticlopidine and clopidogrel, sometimes combined with aspirin, only minimally increase the surgical risk in renal transplantation: A case-control study. Nephrol Dial Transplant, 2014. 29: 463.

93.Osman, Y., et al. Necessity of Routine Postoperative Heparinization in Non-Risky Live-Donor Renal Transplantation: Results of a Prospective Randomized Trial. Urology, 2007. 69: 647.

94.Orlando, G., et al. One-shot versus multidose perioperative antibiotic prophylaxis after kidney transplantation: a randomized, controlled clinical trial. Surgery, 2015. 157: 104.

95.Choi, S.U., et al. Clinical significance of prophylactic antibiotics in renal transplantation. Transplant Proc, 2013. 45: 1392.

96.O’Malley, C.M., et al. A randomized, double-blind comparison of lactated Ringer’s solution and 0.9% NaCl during renal transplantation. Anesth Analg, 2005. 100: 1518.

97.Othman, M.M., et al. The impact of timing of maximal crystalloid hydration on early graft function during kidney transplantation. Anesth Analg, 2010. 110: 1440.

98.Dalton, R.S., et al. Physiologic impact of low-dose dopamine on renal function in the early post renal transplant period. Transplantation, 2005. 79: 1561.

99.Ciapetti, M., et al. Low-dose dopamine in kidney transplantation. Transplant Proc, 2009. 41: 4165.

100.Hanif, F., et al. Outcome of renal transplantation with and without intra-operative diuretics. Int
J Surg, 2011. 9: 460.

101.Valeriani, G., et al. Bench surgery in right kidney transplantation. Transplant Proc, 2010. 42: 1120.

102.Wagenaar, S., et al. Minimally Invasive, Laparoscopic, and Robotic-assisted Techniques Versus Open Techniques for Kidney Transplant Recipients: A Systematic Review. Eur Urol, 2017. 72: 205.

103.Chedid, M.F., et al. Living donor kidney transplantation using laparoscopically procured multiple renal artery kidneys and right kidneys. J Am Coll Surg, 2013. 217: 144.

104.Kaminska, D., et al. The influence of warm ischemia elimination on kidney injury during transplantation - clinical and molecular study. Sci Rep, 2016. 6: 36118.

105.Ozdemir-van Brunschot, D.M., et al. Is the Reluctance for the Implantation of Right Donor Kidneys Justified? World J Surg, 2016. 40: 471.

106.Khalil, A., et al. Trends and outcomes in right vs. left living donor nephrectomy: an analysis of the OPTN/UNOS database of donor and recipient outcomes--should we be doing more right-sided nephrectomies? Clin Transplant, 2016. 30: 145.

107.Hsu, J.W., et al. Increased early graft failure in right-sided living donor nephrectomy. Transplantation, 2011. 91: 108.

108.Kulkarni, S., et al. Outcomes From Right Versus Left Deceased-Donor Kidney Transplants: A US National Cohort Study. Am J Kidney Dis, 2020. 75: 725.

109.Wang, K., et al. Right Versus Left Laparoscopic Living-Donor Nephrectomy: A Meta-Analysis. Exp Clin Transplant, 2015. 13: 214.

110.Ciudin, A., et al. Transposition of iliac vessels in implantation of right living donor kidneys. Transplant Proc, 2012. 44: 2945.

111.Phelan, P.J., et al. Left versus right deceased donor renal allograft outcome. Transpl Int, 2009.
22: 1159.

112.Feng, J.Y., et al. Renal vein lengthening using gonadal vein reduces surgical difficulty in living-donor kidney transplantation. World J Surg, 2012. 36: 468.

113.Nghiem, D.D. Use of spiral vein graft in living donor renal transplantation. Clin Transplant, 2008. 22: 719.

114.Matheus, W.E., et al. Kidney transplant anastomosis: internal or external iliac artery? Urol J, 2009.
6: 260.

115.El-Sherbiny, M., et al. The use of the inferior epigastric artery for accessory lower polar artery revascularization in live donor renal transplantation. Int Urol Nephrol, 2008. 40: 283.

116.Firmin, L.C., et al. The use of explanted internal iliac artery grafts in renal transplants with multiple arteries. Transplantation, 2010. 89: 766.

117.Oertl, A.J., et al. Saphenous vein interposition as a salvage technique for complex vascular situations during renal transplantation. Transplant Proc, 2007. 39: 140.

118.Tozzi, M., et al. Treatment of aortoiliac occlusive or dilatative disease concomitant with kidney transplantation: how and when? Int J Surg, 2013. 11 Suppl 1: S115.

119.Franchin, M., et al. ePTFE suture is an effective tool for vascular anastomosis in kidney transplantation. Ital J Vasc Endovasc Surg, 2015. 22: 61.

120.Izquierdo, L., et al. Third and fourth kidney transplant: still a reasonable option. Transplant Proc, 2010. 42: 2498.

121.Blanco, M., et al. Third kidney transplantation: a permanent medical-surgical challenge. Transplant Proc, 2009. 41: 2366.

122.Nourbala, M.H., et al. Our experience with third renal transplantation: results, surgical techniques and complications. Int J Urol, 2007. 14: 1057.

123.Musquera, M., et al. Orthotopic kidney transplantation: an alternative surgical technique in selected patients. Eur Urol, 2010. 58: 927.

124.Heylen, L., et al. The Impact of Anastomosis Time During Kidney Transplantation on Graft Loss: A Eurotransplant Cohort Study. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2017. 17: 724.

125.Weissenbacher, A., et al. The faster the better: anastomosis time influences patient survival after deceased donor kidney transplantation. Transpl Int, 2015. 28: 535.

126.McCulloch, P., et al. IDEAL framework for surgical innovation 1: the idea and development stages. BMJ, 2013. 346: f3012.

127.Breda, A., et al. Robot-assisted Kidney Transplantation: The European Experience [Figure presented]. Eur Urol, 2018. 73: 273.

128.Gallioli, A., et al. Learning Curve in Robot-assisted Kidney Transplantation: Results from the European Robotic Urological Society Working Group. Eur Urol, 2020.

129.Tzvetanov, I.G., et al. Robotic kidney transplantation in the obese patient: 10-year experience from a single center. Am J Transplant, 2020. 20: 430.

130.Basu, A., et al. Adult dual kidney transplantation. Curr Opin Organ Transplant, 2007. 12: 379.

131.Haider, H.H., et al. Dual kidney transplantation using midline extraperitoneal approach: description of a technique. Transplant Proc, 2007. 39: 1118.

132.Ekser, B., et al. Technical aspects of unilateral dual kidney transplantation from expanded criteria donors: experience of 100 patients. Am J Transplant, 2010. 10: 2000.

133.Nghiem, D.D. Simultaneous double adult kidney transplantation using single arterial and venous anastomoses. Urology, 2006. 67: 1076.

134.Veroux, P., et al. Two-as-one monolateral dual kidney transplantation. Urology, 2011. 77: 227.

135.Salehipour, M., et al. En-bloc Transplantation: an Eligible Technique for Unilateral Dual Kidney Transplantation. Int J Organ Transplant Med, 2012. 3: 111.

136.Rigotti, P., et al. A single-center experience with 200 dual kidney transplantations. Clin Transplant, 2014. 28: 1433.

137.Al-Shraideh, Y., et al. Single vs dual (en bloc) kidney transplants from donors </= 5 years of age: A single center experience. World J Transplant, 2016. 6: 239.

138.Alberts, V.P., et al. Ureterovesical anastomotic techniques for kidney transplantation: a systematic review and meta-analysis. Transpl Int, 2014. 27: 593.

139.Slagt, I.K., et al. A randomized controlled trial comparing intravesical to extravesical ureteroneocystostomy in living donor kidney transplantation recipients. Kidney Int, 2014. 85: 471.

140.Timsit, M.O., et al. Should routine pyeloureterostomy be advocated in adult kidney transplantation? A prospective study of 283 recipients. J Urol, 2010. 184: 2043.

141.Suttle, T., et al. Comparison of urologic complications between ureteroneocystostomy and ureteroureterostomy in renal transplant: A meta-analysis. Exp Clin Transplant, 2016. 14: 276.

142.Dadkhah, F., et al. Modified ureteroneocystostomy in kidney transplantation to facilitate endoscopic management of subsequent urological complications. Int Urol Nephrol, 2010. 42: 285.

143.Kehinde, E.O., et al. Complications associated with using nonabsorbable sutures for ureteroneocystostomy in renal transplant operations. Transplant Proc, 2000. 32: 1917.

144.Wilson, C.H., et al. Routine intraoperative ureteric stenting for kidney transplant recipients. Cochrane Database Syst Rev, 2013: CD004925.

145.Tavakoli, A., et al. Impact of stents on urological complications and health care expenditure in renal transplant recipients: results of a prospective, randomized clinical trial. J Urol, 2007. 177: 2260.

146.Cai, J.F., et al. Meta-analysis of Early Versus Late Ureteric Stent Removal After Kidney Transplantation. Transplant Proc, 2018. 50: 3411.

147.Visser, I.J., et al. Timing of Ureteric Stent Removal and Occurrence of Urological Complications after Kidney Transplantation: A Systematic Review and Meta-Analysis. J Clin Med, 2019. 8.

148.Patel, P., et al. Prophylactic Ureteric Stents in Renal Transplant Recipients: A Multicenter Randomized Controlled Trial of Early Versus Late Removal. Am J Transplant, 2017. 17: 2129.

149.Heidari, M., et al. Transplantation of kidneys with duplicated ureters. Scand J Urol Nephrol, 2010. 44: 337.

150.Alberts, V.P., et al. Duplicated ureters and renal transplantation: a case-control study and review of the literature. Transplant Proc, 2013. 45: 3239.

151.Surange, R.S., et al. Kidney transplantation into an ileal conduit: a single center experience of
59 cases. J Urol, 2003. 170: 1727.

152.Kortram, K., et al. Perioperative Events and Complications in Minimally Invasive Live Donor Nephrectomy: A Systematic Review and Meta-Analysis. Transplantation, 2016.

153.Segev, D.L., et al. Perioperative mortality and long-term survival following live kidney donation. JAMA, 2010. 303: 959.

154.Chu, K.H., et al. Long-term outcomes of living kidney donors: a single centre experience of
29 years. Nephrology (Carlton), 2012. 17: 85.

155.Fehrman-Ekholm, I., et al. Post-nephrectomy development of renal function in living kidney donors: a cross-sectional retrospective study. Nephrol Dial Transplant, 2011. 26: 2377.

156.Li, S.S., et al. A meta-analysis of renal outcomes in living kidney donors. [Review]. Medicine, 2016. 95.

157.Thiel, G.T., et al. Investigating kidney donation as a risk factor for hypertension and microalbuminuria: findings from the Swiss prospective follow-up of living kidney donors. BMJ Open, 2016. 6: 22.

158.Ibrahim, H.N., et al. Long-term consequences of kidney donation. N Engl J Med, 2009. 360: 459.

159.Li, S.S., et al. A meta-analysis of renal outcomes in living kidney donors. Medicine (Baltimore), 2016. 95: e3847.

160.Matas, A.J., et al. Causes and timing of end-stage renal disease after living kidney donation. Am
J Transplant, 2018. 18: 1140.

161.Locke, J.E., et al. Obesity increases the risk of end-stage renal disease among living kidney donors. Kidney Int, 2017. 91: 699.

162.Gross, C.R., et al. Health-related quality of life in kidney donors from the last five decades: results from the RELIVE study. Am J Transplant, 2013. 13: 2924.

163.Maggiore, U., et al. Long-term risks of kidney living donation: Review and position paper by the ERA-EDTA DESCARTES working group. Nephrol Dial Transplant, 2017. 32: 216.

164.Lorenz, E.C., et al. The impact of urinary tract infections in renal transplant recipients. Kidney Int, 2010. 78: 719.

165.Ariza-Heredia, E.J., et al. Urinary tract infections in kidney transplant recipients: role of gender, urologic abnormalities, and antimicrobial prophylaxis. Ann Transplant, 2013. 18: 195.

166.Chang, C.Y., et al. Urological manifestations of BK polyomavirus in renal transplant recipients. Can
J Urol, 2005. 12: 2829.

167.Hwang, J.K., et al. Comparative analysis of ABO-incompatible living donor kidney transplantation with ABO-compatible grafts: a single-center experience in Korea. Transplant Proc, 2013. 45: 2931.

168.Habicht, A., et al. Increase of infectious complications in ABO-incompatible kidney transplant recipients--a single centre experience. Nephrol Dial Transplant, 2011. 26: 4124.

169.Sorto, R., et al. Risk factors for urinary tract infections during the first year after kidney transplantation. Transplant Proc, 2010. 42: 280.

170.Thrasher, J.B., et al. Extravesical versus Leadbetter-Politano ureteroneocystostomy: a comparison of urological complications in 320 renal transplants. J Urol, 1990. 144: 1105.

171.Mangus, R.S., et al. Stented versus nonstented extravesical ureteroneocystostomy in renal transplantation: a metaanalysis. Am J Transplant, 2004. 4: 1889.

172.Wilson, C.H., et al. Routine intraoperative ureteric stenting for kidney transplant recipients. Cochrane Database Syst Rev, 2005: CD004925.

173.Osman, Y., et al. Routine insertion of ureteral stent in live-donor renal transplantation: is it worthwhile? Urology, 2005. 65: 867.

174.Georgiev, P., et al. Routine stenting reduces urologic complications as compared with stenting “on demand” in adult kidney transplantation. Urology, 2007. 70: 893.

175.Akoh, J.A., et al. Effect of ureteric stents on urological infection and graft function following renal transplantation. World J Transplant, 2013. 3: 1.

176.Fayek, S.A., et al. Ureteral stents are associated with reduced risk of ureteral complications after kidney transplantation: a large single center experience. Transplantation, 2012. 93: 304.

177.Dimitroulis, D., et al. Vascular complications in renal transplantation: a single-center experience in 1367 renal transplantations and review of the literature. Transplant Proc, 2009. 41: 1609.

178.Pawlicki, J., et al. Risk factors for early hemorrhagic and thrombotic complications after kidney transplantation. Transplant Proc, 2011. 43: 3013.

179.Rouviere, O., et al. Acute thrombosis of renal transplant artery: graft salvage by means of intra-arterial fibrinolysis. Transplantation, 2002. 73: 403.

180.Domagala, P., et al. Complications of transplantation of kidneys from expanded-criteria donors. Transplant Proc, 2009. 41: 2970.

181.Ammi, M., et al. Evaluation of the Vascular Surgical Complications of Renal Transplantation. Annals of Vascular Surgery, 2016. 33: 23.

182.Giustacchini, P., et al. Renal vein thrombosis after renal transplantation: an important cause of graft loss. Transplant Proc, 2002. 34: 2126.

183.Wuthrich, R.P. Factor V Leiden mutation: potential thrombogenic role in renal vein, dialysis graft and transplant vascular thrombosis. Curr Opin Nephrol Hypertens, 2001. 10: 409.

184.Parajuli, S., et al. Hypercoagulability in Kidney Transplant Recipients. Transplantation, 2016. 100: 719.

185.Granata, A., et al. Renal transplant vascular complications: the role of Doppler ultrasound.
J Ultrasound, 2015. 18: 101.

186.Hogan, J.L., et al. Late-onset renal vein thrombosis: A case report and review of the literature. Int
J Surg Case Rep, 2015. 6C: 73.

187.Musso, D., et al. Symptomatic Venous Thromboembolism and Major Bleeding After Renal Transplantation: Should We Use Pharmacologic Thromboprophylaxis? Transplantation Proceedings, 2016. 48: 2773.

188.Hurst, F.P., et al. Incidence, predictors and outcomes of transplant renal artery stenosis after kidney transplantation: analysis of USRDS. Am J Nephrol, 2009. 30: 459.

189.Willicombe, M., et al. Postanastomotic transplant renal artery stenosis: association with de novo class II donor-specific antibodies. Am J Transplant, 2014. 14: 133.

190.Ghazanfar, A., et al. Management of transplant renal artery stenosis and its impact on long-term allograft survival: a single-centre experience. Nephrol Dial Transplant, 2011. 26: 336.

191.Seratnahaei, A., et al. Management of transplant renal artery stenosis. Angiology, 2011. 62: 219.

192.Rountas, C., et al. Imaging modalities for renal artery stenosis in suspected renovascular hypertension: prospective intraindividual comparison of color Doppler US, CT angiography, GD-enhanced MR angiography, and digital substraction angiography. Ren Fail, 2007. 29: 295.

193.Fervenza, F.C., et al. Renal artery stenosis in kidney transplants. Am J Kidney Dis, 1998. 31: 142.

194.Bach, D., et al. Percutaneous renal biopsy: three years of experience with the biopty gun in 761 cases--a survey of results and complications. Int Urol Nephrol, 1999. 31: 15.

195.Loffroy, R., et al. Management of post-biopsy renal allograft arteriovenous fistulas with selective arterial embolization: immediate and long-term outcomes. Clin Radiol, 2008. 63: 657.

196.Atray, N.K., et al. Post transplant lymphocele: a single centre experience. Clin Transplant, 2004.
18 Suppl 12: 46.

197.Ulrich, F., et al. Symptomatic lymphoceles after kidney transplantation - multivariate analysis of risk factors and outcome after laparoscopic fenestration. Clin Transplant, 2010. 24: 273.

198.Lucewicz, A., et al. Management of primary symptomatic lymphocele after kidney transplantation: a systematic review. Transplantation, 2011. 92: 663.

199.Capocasale, E., et al. Octreotide in the treatment of lymphorrhea after renal transplantation: a preliminary experience. Transplant Proc, 2006. 38: 1047.

200.Kayler, L., et al. Kidney transplant ureteroneocystostomy techniques and complications: review of the literature. Transplant Proc, 2010. 42: 1413.

201.Secin, F.P., et al. Comparing Taguchi and Lich-Gregoir ureterovesical reimplantation techniques for kidney transplants. J Urol, 2002. 168: 926.

202.Dinckan, A., et al. Early and late urological complications corrected surgically following renal transplantation. Transpl Int, 2007. 20: 702.

203.Kumar, A., et al. Evaluation of the urological complications of living related renal transplantation at
a single center during the last 10 years: impact of the Double-J* stent. J Urol, 2000. 164: 657.

204.Mazzucchi, E., et al. Primary reconstruction is a good option in the treatment of urinary fistula after kidney transplantation. Int Braz J Urol, 2006. 32: 398.

205.Davari, H.R., et al. Urological complications in 980 consecutive patients with renal transplantation. Int J Urol, 2006. 13: 1271.

206.Sabnis, R.B., et al. The development and current status of minimally invasive surgery to manage urological complications after renal transplantation. Indian J Urol, 2016. 32: 186.

207.Breda, A., et al. Incidence of ureteral strictures after laparoscopic donor nephrectomy. J Urol, 2006. 176: 1065.

208.Helfand, B.T., et al. Reconstruction of late-onset transplant ureteral stricture disease. BJU Int, 2011. 107: 982.

209.Kaskarelis, I., et al. Ureteral complications in renal transplant recipients successfully treated with interventional radiology. Transplant Proc, 2008. 40: 3170.

210.Gabr, A.H., et al. Ureteral complications after hand-assisted laparoscopic living donor nephrectomy. Transplantation, 2014. 97: 788.

211.Kristo, B., et al. Treatment of renal transplant ureterovesical anastomotic strictures using antegrade balloon dilation with or without holmium:YAG laser endoureterotomy. Urology, 2003. 62: 831.

212.Nie, Z., et al. Comparison of urological complications with primary ureteroureterostomy versus conventional ureteroneocystostomy. Clin Transplant, 2010. 24: 615.

213.Chaykovska, L., et al. Kidney transplantation into urinary conduits with ureteroureterostomy between transplant and native ureter: single-center experience. Urology, 2009. 73: 380.

214.Kumar, S., et al. Long-term graft and patient survival after balloon dilation of ureteric stenosis after renal transplant: A 23-year retrospective matched cohort study. Radiology, 2016. 281: 301.

215.Jung, G.O., et al. Clinical significance of posttransplantation vesicoureteral reflux during short-term period after kidney transplantation. Transplant Proc, 2008. 40: 2339.

216.Giral, M., et al. Acute graft pyelonephritis and long-term kidney allograft outcome. Kidney Int, 2002. 61: 1880.

217.Pichler, R., et al. Endoscopic application of dextranomer/hyaluronic acid copolymer in the treatment of vesico-ureteric reflux after renal transplantation. BJU Int, 2011. 107: 1967.

218.Abbott, K.C., et al. Hospitalized nephrolithiasis after renal transplantation in the United States. Am
J Transplant, 2003. 3: 465.

219.Verrier, C., et al. Decrease in and management of urolithiasis after kidney transplantation. J Urol, 2012. 187: 1651.

220.Oliveira, M., et al. Percutaneous nephrolithotomy in renal transplants: a safe approach with a high stone-free rate. Int Urol Nephrol, 2011. 43: 329.

221.Silva, A., et al. Risk factors for urinary tract infection after renal transplantation and its impact on graft function in children and young adults. J Urol, 2010. 184: 1462.

222.Challacombe, B., et al. Multimodal management of urolithiasis in renal transplantation. BJU Int, 2005. 96: 385.

223.Basiri, A., et al. Ureteroscopic management of urological complications after renal transplantation. Scand J Urol Nephrol, 2006. 40: 53.

224.Roine, E., et al. Targeting risk factors for impaired wound healing and wound complications after kidney transplantation. Transplant Proc, 2010. 42: 2542.

225.Yannam, G.R., et al. Experience of laparoscopic incisional hernia repair in kidney and/or pancreas transplant recipients. Am J Transplant, 2011. 11: 279.

226.Boissier, R., et al. The Risk of Tumour Recurrence in Patients Undergoing Renal Transplantation for End-stage Renal Disease after Previous Treatment for a Urological Cancer: A Systematic Review. Eur Urol, 2018. 73: 94.

227.Hevia, V., et al. Effectiveness and Harms of Using Kidneys with Small Renal Tumors from Deceased or Living Donors as a Source of Renal Transplantation: A Systematic Review. Eur Urol Focus, 2018.

228.Hevia, V., et al. Management of Localised Prostate Cancer in Kidney Transplant Patients: A Systematic Review from the EAU Guidelines on Renal Transplantation Panel. Eur Urol Focus, 2018. 4: 153.

229.Marra, G., et al. Prostate cancer treatment in renal transplant recipients: a systematic review. BJU Int, 2018. 121: 327.

230.Tait, B.D., et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation, 2013. 95: 19.

231.European Renal Best Practice Transplantation Guideline Development Group. ERBP Guideline on the Management and Evaluation of the Kidney Donor and Recipient. Nephrol Dial Transplant, 2013. 28 Suppl 2: ii1.

232.Poulton, K., et al. British Transplantation Society. Guidelines for the detection of clinically relevant antibodies in allotransplantation. 2014.

233.UNOS. Unitied Network For Organ Sharing Website:

234.Heidt, S., Eurotransplant Manual version 3.1 Chapter 10 Histocompatibility. 2015.

235.European Federation for Immunogenetics, EFI Standards for Histocompatibility and Immunogenetics Testing Version 6.3. 2015.

236.De Meester, J., et al. Renal transplantation of highly sensitised patients via prioritised renal allocation programs. Shorter waiting time and above-average graft survival. Nephron, 2002. 92: 111.

237.Susal, C., et al. Algorithms for the determination of unacceptable HLA antigen mismatches in kidney transplant recipients. Tissue Antigens, 2013. 82: 83.

238.Bohmig, G.A., et al. Strategies to overcome the ABO barrier in kidney transplantation. Nat Rev Nephrol, 2015. 11: 732.

239.Zschiedrich, S., et al. An update on ABO-incompatible kidney transplantation. Transpl Int, 2015.
28: 387.

240.Higgins, R.M., et al. Antibody-incompatible kidney transplantation in 2015 and beyond. Nephrol Dial Transplant, 2015. 30: 1972.

241.Wongsaroj, P., et al. Modern approaches to incompatible kidney transplantation. World J Nephrol, 2015. 4: 354.

242.Bamoulid, J., et al. Immunosuppression and Results in Renal Transplantation. European Urology Supplements, 2016. 15: 415.

243.Kidney Disease Improving Global Outcomes Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant, 2009. 9 Suppl 3: S1.

244.Bamoulid, J., et al. The need for minimization strategies: current problems of immunosuppression. Transpl Int, 2015. 28: 891.

245.Jones-Hughes, T., et al. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model. Health Technol Assess, 2016. 20: 1.

246.Leas, B.F., et al., Calcineurin Inhibitors for Renal Transplant. 2016: Rockville (MD): AHRQ.

247.Sawinski, D., et al. Calcineurin Inhibitor Minimization, Conversion, Withdrawal, and Avoidance Strategies in Renal Transplantation: A Systematic Review and Meta-Analysis. Am J Transplant, 2016. 16: 2117.

248.Webster, A.C., et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ, 2005. 331: 810.

249.Brunet, M., et al. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Therapeutic Drug Monitoring, 2019. 41: 261.

250.Ekberg, H., et al. Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation. Transplantation, 2011. 92: 82.

251.Xia, T., et al. Risk factors for calcineurin inhibitor nephrotoxicity after renal transplantation: A systematic review and meta-analysis. Drug Des Devel Ther, 2018. 12: 417.

252.Gallagher, M., et al. Cyclosporine withdrawal improves long-term graft survival in renal transplantation. Transplantation, 2009. 87: 1877.

253.Liu, J.Y., et al. Tacrolimus versus cyclosporine as primary immunosuppressant after renal transplantation: A meta-analysis and economics evaluation. Am J Ther, 2016. 23: e810.

254.Opelz, G., et al. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation, 2009. 87: 795.

255.Cheung, C.Y., et al. Long-term graft function with tacrolimus and cyclosporine in renal transplantation: Paired kidney analysis. Nephrology, 2009. 14: 758. Fijter, J.W., et al. Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial. Am J Transplant, 2017. 17: 1853.

257.Goring, S.M., et al. A network meta-analysis of the efficacy of belatacept, cyclosporine and tacrolimus for immunosuppression therapy in adult renal transplant recipients. Cur Med Res Opin, 2014. 30: 1473.

258.Pascual, J., et al. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. J Am Soc Nephrol: JASN, 2018. 29: 1979.

259.Basso, G., et al. The effect of anti-thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients without prophylaxis. Transpl Infect Dis, 2018. 20: e12919.

260.Bloom, R.D., et al. A randomized, crossover pharmacokinetic study comparing generic tacrolimus vs. the reference formulation in subpopulations of kidney transplant patients. Clin Transplant, 2013. 27: E685.

261.Glander, P., et al. Bioavailability and costs of once-daily and twice-daily tacrolimus formulations in de novo kidney transplantation. Clin Transplant, 2018: e13311.

262.Guirado, L., et al. Medium-Term Renal Function in a Large Cohort of Stable Kidney Transplant Recipients Converted From Twice-Daily to Once-Daily Tacrolimus. Transplant Dir, 2015. 1: e24.

263.Melilli, E., et al. De novo use of a generic formulation of tacrolimus versus reference tacrolimus in kidney transplantation: Evaluation of the clinical results, histology in protocol biopsies, and immunological monitoring. Transplant Int, 2015. 28: 1283.

264.Robertsen, I., et al. Use of generic tacrolimus in elderly renal transplant recipients: Precaution is needed. Transplantation, 2015. 99: 528.

265.Rostaing, L., et al. Novel once-daily extended-release tacrolimus versus twice-daily tacrolimus in de novo kidney transplant recipients: Two-year results of phase 3, double-blind, randomized trial. Am
J Kidney Dis, 2016. 67: 648.

266.Saengram, W., et al. Extended release versus immediate release tacrolimus in kidney transplant recipients: a systematic review and meta-analysis. Eur J Clin Pharmacol, 2018: 1.

267.Silva, H.T., et al. Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients. Transplantation, 2014. 97: 636.

268.Kahn, J., et al. Immunosuppression with generic tacrolimus in liver and kidney transplantation-systematic review and meta-analysis on biopsy-proven acute rejection and bioequivalence. Transplant Int, 2020. 33: 356.

269.Lehner, L.J., et al. Evaluation of adherence and tolerability of prolonged-release tacrolimus (AdvagrafTM) in kidney transplant patients in Germany: A multicenter, noninterventional study. Clin Transplant, 2018. 32: e13142.

270.Paterson, T.S.E., et al. Impact of Once- Versus Twice-Daily Tacrolimus Dosing on Medication Adherence in Stable Renal Transplant Recipients: A Canadian Single-Center Randomized Controlled Trial. Can J Kidney Health, 2019. 6.

271.Caillard, S., et al. Advagraf((R)) , a once-daily prolonged release tacrolimus formulation, in kidney transplantation: literature review and guidelines from a panel of experts. Transpl Int, 2016. 29: 860.

272.McCormack, P.L. Extended-release tacrolimus: a review of its use in de novo kidney transplantation. Drugs, 2014. 74: 2053.

273.Molnar, A.O., et al. Generic immunosuppression in solid organ transplantation: systematic review and meta-analysis. BMJ, 2015. 350: h3163.

274.Staatz, C.E., et al. Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients. Clin Pharmacokinet, 2015. 54: 993.

275.van Gelder, T., et al. European Society for Organ Transplantation Advisory Committee recommendations on generic substitution of immunosuppressive drugs. Transpl Int, 2011. 24: 1135.

276.Wissing, K.M., et al. Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation. Am J Transplant, 2018. 18: 1726.

277.Diekmann, F. Immunosuppressive minimization with mTOR inhibitors and belatacept. Transpl Int, 2015. 28: 921.

278.Kamar, N., et al. Calcineurin inhibitor-sparing regimens based on mycophenolic acid after kidney transplantation. Transpl Int, 2015. 28: 928.

279.Park, S., et al. Reduced Tacrolimus Trough Level Is Reflected by Estimated Glomerular Filtration Rate (eGFR) Changes in Stable Renal Transplantation Recipients: Results of the OPTIMUM Phase 3 Randomized Controlled Study. Ann Transplantn, 2018. 23: 401.

280.Sharif, A., et al. Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation.,
J Am Soc Nephrol 2011. 22: 2107.

281.Snanoudj, R., et al. Immunological risks of minimization strategies. Transpl Int, 2015. 28: 901.

282.Etienne, I., et al. A 50% reduction in cyclosporine exposure in stable renal transplant recipients: Renal function benefits. Nephrol Dial Transplant, 2010. 25: 3096.

283.Budde, K., et al. Enteric-coated mycophenolate sodium. Expert Opin Drug Saf, 2010. 9: 981.

284.Cooper, M., et al. Enteric-coated mycophenolate sodium immunosuppression in renal transplant patients: efficacy and dosing. Transplant Rev (Orlando), 2012. 26: 233.

285.Staatz, C.E., et al. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. Arch Toxicol, 2014. 88: 1351.

286.van Gelder, T., et al. Mycophenolate revisited. Transpl Int, 2015. 28: 508.

287.Wagner, M., et al. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev, 2015: CD007746.

288.Hirsch, H.H., et al. European perspective on human polyomavirus infection, replication and disease in solid organ transplantation. Clin Microbiol Infect, 2014. 20 Suppl 7: 74.

289.Langone, A.J., et al. Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: A multicenter, double-blind, randomized study. Transplantation, 2011. 91: 470.

290.Doria, C., et al. Association of mycophenolic acid dose with efficacy and safety events in kidney transplant patients receiving tacrolimus: An analysis of the Mycophenolic acid Observational REnal transplant registry. Clin Transplant, 2012. 26: E602.

291.Langone, A., et al. Does reduction in mycophenolic acid dose compromise efficacy regardless of tacrolimus exposure level? An analysis of prospective data from the Mycophenolic Renal Transplant (MORE) Registry. Clin Transplant, 2013. 27: 15.

292.Su, V.C.H., et al. Impact of mycophenolate mofetil dose reduction on allograft outcomes in kidney transplant recipients on tacrolimus-based regimens: A systematic review. Ann Pharmacother, 2011. 45: 248.

293.Kotton, C.N., et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation, 2013. 96: 333.

294.Le Meur, Y., et al. Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meeting. Transplant Rev (Orlando), 2011. 25: 58.

295.Haller, M.C., et al. Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev, 2016: CD005632.

296.Meier-Kriesche, H.U., et al. Mycophenolate mofetil initiation in renal transplant patients at different times posttransplantation: The TranCept switch study. Transplantation, 2011. 91: 984.

297.Mathis, A.S., et al. Calcineurin inhibitor sparing strategies in renal transplantation, part one: Late sparing strategies. World J Transplant, 2014. 4: 57.

298.Remuzzi, G., et al. Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial. J Am Soc Nephrol, 2007. 18: 1973.

299.Kunz, R., et al. Maintenance therapy with triple versus double immunosuppressive regimen in renal transplantation: a meta-analysis. Transplantation, 1997. 63: 386.

300.Le Meur, Y., et al. Early steroid withdrawal and optimization of mycophenolic acid exposure in kidney transplant recipients receiving mycophenolate mofetil. Transplantation, 2011. 92: 1244.

301.Suszynski, T.M., et al. Prospective randomized trial of maintenance immunosuppression with rapid discontinuation of prednisone in adult kidney transplantation. Am J Transplant, 2013. 13: 961.

302.Thomusch, O., et al. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial. Lancet, 2016. 388: 3006.

303.Torres, A., et al. Randomized Controlled Trial Assessing the Impact of Tacrolimus Versus Cyclosporine on the Incidence of Posttransplant Diabetes Mellitus. Kidney Int Reports, 2018. 3: 1304.

304.Halleck, F., et al. An evaluation of sirolimus in renal transplantation. Expert Opin Drug Metab Toxicol, 2012. 8: 1337.

305.Ventura-Aguiar, P., et al. Safety of mTOR inhibitors in adult solid organ transplantation. Expert Opin Drug Saf, 2016. 15: 303.

306.Witzke, O., et al. Everolimus immunosuppression in kidney transplantation: What is the optimal strategy? Transplant Rev (Orlando), 2016. 30: 3.

307.Montero, N., et al. Mammalian Target of Rapamycin Inhibitors Combined with Calcineurin Inhibitors as Initial Immunosuppression in Renal Transplantation: A Meta-analysis. Transplantation, 2019. 103: 2031.

308.Badve, S.V., et al. Mammalian target of rapamycin inhibitors and clinical outcomes in adult kidney transplant recipients. Clin J Am Soc Nephrol, 2016. 11: 1845.

309.Lim, W.H., et al. A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients. Am
J Transplant, 2014. 14: 2106.

310.Liu, J., et al. Efficacy and safety of everolimus for maintenance immunosuppression of kidney transplantation: A meta-analysis of randomized controlled trials. PLoS ONE, 2017. 12: e0170246.

311.Knoll, G.A., et al. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ, 2014. 349: g6679.

312.Xie, X., et al. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis. BMC Nephrol, 2015. 16: 91.

313.Wolf, S., et al. Effects of mTOR-Is on malignancy and survival following renal transplantation: A systematic review and meta-analysis of randomized trials with a minimum follow-up of 24 months. PLoS One, 2018. 13: e0194975.

314.Hahn, D., et al. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. Cochrane Database Syst Rev, 2019. 2019: CD004290.

315.Shipkova, M., et al. Therapeutic Drug Monitoring of Everolimus: A Consensus Report. Ther Drug Monit, 2016. 38: 143.

316.Rostaing, L., et al. The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: An analysis from the randomized ASSET study. Ann Transplant, 2014. 19: 337.

317.Shihab, F., et al. Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus. Am J Transplant, 2017. 17: 2363.

318.Kumar, J., et al. Systematic review on role of mammalian target of rapamycin inhibitors as an alternative to calcineurin inhibitors in renal transplant: Challenges and window to excel. Exp Clin Transplant, 2017. 15: 241.

319.Qazi, Y., et al. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data. Am J Transplant, 2017. 17: 1358.

320.Rummo, O.O., et al. ADHERE: randomized controlled trial comparing renal function in de novo kidney transplant recipients receiving prolonged-release tacrolimus plus mycophenolate mofetil or sirolimus. Transplant Int, 2017. 30: 83.

321.Berger, S.P., et al. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study. Am J Transplant, 2019. 19: 3018.

322.Sommerer, C., et al. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients. Kidney Int, 2019. 96: 231.

323.Tedesco-Silva, H., et al. Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study. Transplantation, 2019. 103: 1953.

324.He, L., et al. Efficacy and safety of everolimus plus lowdose calcineurin inhibitor vs. mycophenolate mofetil plus standard-dose calcineurin inhibitor in renal transplant recipients: A systematic review and meta-analysis. Clin Nephrol, 2018. 89: 336.

325.Liu, J.Y., et al. Sirolimus versus tacrolimus as primary immunosuppressant after renal transplantation: A meta-analysis and economics evaluation. Am J Ther, 2016. 23: e1720.

326.Zhao, D.Q., et al. Sirolimus-based immunosuppressive regimens in renal transplantation: A systemic review. Transplant Proc, 2016. 48: 3.

327.Liefeldt, L., et al. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant, 2012. 12: 1192.

328.Wolf, S., et al. Infections after kidney transplantation: A comparison of mTOR-Is and CNIs as basic immunosuppressants. A systematic review and meta-analysis. Transpl Infect Dis, 2020.

329.Halleck, F., et al. Transplantation: Sirolimus for secondary SCC prevention in renal transplantation. Nat Rev Nephrol, 2012. 8: 687.

330.Ponticelli, C., et al. Skin cancer in kidney transplant recipients. J Nephrol, 2014. 27: 385.

331.Cheung, C.Y., et al. Conversion to mammalian target of rapamycin inhibitors in kidney transplant recipients with de novo cancers. Oncotarget, 2017. 8: 44833.

332.Opelz, G., et al. Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients. Nephrol Dial Transplant, 2016. 31: 1360.

333.Liu, Y., et al. Basiliximab or antithymocyte globulin for induction therapy in kidney transplantation: a meta-analysis. Transplant Proc, 2010. 42: 1667.

334.Sun, Z.J., et al. Efficacy and Safety of Basiliximab Versus Daclizumab in Kidney Transplantation: A Meta-Analysis. Transplant Proc, 2015. 47: 2439.

335.Webster, A.C., et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev, 2010: CD003897.

336.Lim, W., et al. Effect of interleukin-2 receptor antibody therapy on acute rejection risk and severity, long-term renal function, infection and malignancy-related mortality in renal transplant recipients. Transplant Int, 2010. 23: 1207.

337.McKeage, K., et al. Basiliximab: A review of its use as induction therapy in renal transplantation. BioDrugs, 2010. 24: 55.

338.Hellemans, R., et al. Induction Therapy for Kidney Transplant Recipients: Do We Still Need Anti-IL2 Receptor Monoclonal Antibodies? Am J Transplant, 2017. 17: 22.

339.Ali, H., et al. Rabbit anti-thymocyte globulin (rATG) versus IL-2 receptor antagonist induction therapies in tacrolimus-based immunosuppression era: a meta-analysis. Int Urol Nephrol, 2020.

340.Bamoulid, J., et al. Anti-thymocyte globulins in kidney transplantation: focus on current indications and long-term immunological side effects. Nephrol Dial Transplant, 2016.

341.Malvezzi, P., et al. Induction by anti-thymocyte globulins in kidney transplantation: a review of the literature and current usage. J Nephropathol, 2015. 4: 110.

342.Hill, P., et al. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients. Cochrane Database of Syst Rev, 2017. 2017: CD004759.

343.Webster, A.C., et al. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients. Cochrane Database of Syst Rev, 2017. 2017: CD004756.

344.Gill, J., et al. Induction immunosuppressive therapy in the elderly kidney transplant recipient in the United States. Clinical Journal of the Am Soc Nephrol, 2011. 6: 1168.

345.Grinyo, J.M., et al. Belatacept utilization recommendations: an expert position. Expert Opin Drug Saf, 2013. 12: 111.

346.Wojciechowski, D., et al. Current status of costimulatory blockade in renal transplantation. Curr Opin Nephrol Hypertens, 2016. 25: 583.

347.Durrbach, A., et al. Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study. Am J Transplant, 2016. 16: 3192.

348.Vincenti, F., et al. Belatacept and Long-Term Outcomes in Kidney Transplantation. N Engl J Med, 2016. 374: 333.

349.De Graav, G.N., et al. A Randomized Controlled Clinical Trial Comparing Belatacept with Tacrolimus after de Novo Kidney Transplantation. Transplantation, 2017. 101: 2571.

350.Masson, P., et al. Belatacept for kidney transplant recipients. The Cochrane database Syst Rev, 2014. 11: CD010699.

351.Talawila, N., et al. Does belatacept improve outcomes for kidney transplant recipients? A systematic review. Transplant Int, 2015. 28: 1251.

352.Bray, R.A., et al. De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies. Am J Transplant, 2018.

353.Grannas, G., et al. Ten years experience with belatacept-based immunosuppression after kidney transplantation. J Clin Med Res, 2014. 6: 98.

354.Schwarz, C., et al. Long-term outcome of belatacept therapy in de novo kidney transplant recipients - A case-match analysis. Transplant Int, 2015. 28: 820.

355.Elhamahmi, D.A., et al. Early Conversion to Belatacept in Kidney Transplant Recipients with Low Glomerular Filtration Rate. Transplantation, 2018. 102: 478.

356.Grinyo, J.M., et al. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial. Am J Kidney Dis, 2017. 69: 587.

357.Darres, A., et al. Conversion to Belatacept in Maintenance Kidney Transplant Patients: A Retrospective Multicenter European Study. Transplantation, 2018. 102: 1545.

358.Bamoulid, J., et al. Advances in pharmacotherapy to treat kidney transplant rejection. Expert Opin Pharmacother, 2015. 16: 1627.

359.Broecker, V., et al. The significance of histological diagnosis in renal allograft biopsies in 2014. Transpl Int, 2015. 28: 136.

360.Halloran, P.F., et al. Molecular assessment of disease states in kidney transplant biopsy samples. Nat Rev Nephrol, 2016. 12: 534.

361.Lentine, K.L., et al. The implications of acute rejection for allograft survival in contemporary U.S. kidney transplantation. Transplantation, 2012. 94: 369.

362.Clayton, P.A., et al. Long-term outcomes after acute rejection in kidney transplant recipients: An Anzdata analysis. J Am Soc Nephrol, 2019. 30: 1697.

363.Loupy, A., et al. The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant, 2020. 20: 2318.

364.Morgan, T.A., et al. Complications of Ultrasound-Guided Renal Transplant Biopsies. Am
J Transplant, 2016. 16: 1298.

365.Redfield, R.R., et al. Nature, timing, and severity of complications from ultrasound-guided percutaneous renal transplant biopsy. Transpl Int, 2016. 29: 167.

366.Bouatou, Y., et al. Response to treatment and long-term outcomes in kidney transplant recipients with acute T cell-mediated rejection. Am J Transplant, 2019. 19: 1972.

367.Schinstock, C.A., et al. Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: the 2019 Expert Consensus From the Transplantion Society Working Group. Transplantation, 2020.

368.Amore, A. Antibody-mediated rejection. Curr Opin Organ Transplant, 2015. 20: 536.

369.Burton, S.A., et al. Treatment of antibody-mediated rejection in renal transplant patients: a clinical practice survey. Clin Transplant, 2015. 29: 118.

370.Haririan, A. Current status of the evaluation and management of antibody-mediated rejection in kidney transplantation. Curr Opin Nephrol Hypertens, 2015. 24: 576.

371.Sautenet, B., et al. One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial. Transplantation, 2016. 100: 391.

372.Loupy, A., et al. Antibody-Mediated Rejection of Solid-Organ Allografts. N Engl J Med, 2018.
379: 1150.

373.Wan, S.S., et al. The Treatment of Antibody-Mediated Rejection in Kidney Transplantation: An Updated Systematic Review and Meta-Analysis. Transplantation, 2018. 102: 557.

374.Kamar, N., et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant, 2010. 10: 89.

375.Velidedeoglu, E., et al. Summary of 2017 FDA Public Workshop: Antibody-mediated Rejection in Kidney Transplantation. Transplantation, 2018. 102: e257.

376.Farrugia, D., et al. Malignancy-related mortality following kidney transplantation is common. Kidney Int, 2014. 85: 1395.

377.Piselli, P., et al. Risk of de novo cancers after transplantation: results from a cohort of 7217 kidney transplant recipients, Italy 1997-2009. Eur J Cancer, 2013. 49: 336.

378.Jardine, A.G., et al. Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet, 2011. 378: 1419.

379.Liefeldt, L., et al. Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk. Transpl Int, 2010. 23: 1191.

380.Nankivell, B.J., et al. Diagnosis and prevention of chronic kidney allograft loss. Lancet, 2011.
378: 1428.

381.Boor, P., et al. Renal allograft fibrosis: biology and therapeutic targets. Am J Transplant, 2015.
15: 863.

382.Westall, G.P., et al. Antibody-mediated rejection. Curr Opin Organ Transplant, 2015. 20: 492.

383.Chapman, J.R. Chronic calcineurin inhibitor nephrotoxicity-lest we forget. Am J Transplant, 2011. 11: 693.